Autopsy report · NCT00547118

The Effects of Rimonabant, on Weight and Metabolic Risk Factors

“Withdrawn due to medication withdrawal from the EMEA”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 4 months before it stopped.
• 17 participants enrolled.
• Results were posted on the registry 5 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Maryland, Baltimore

Sponsor type

University, hospital or other

Conditions

Schizophrenia; Schizoaffective Disorder; Obesity; Hypertension; Smoking

Interventions

Rimonabant; Placebo

Participants

17

Sites

4

Countries

United States

Trials that died the same way

• Lapatinib and Bortezomib in Patients With Advanced Malignancies
  “Drug support withdrawn” (71% match in meaning)
• SMMART Adaptive Clinical Treatment (ACT) Trial
  “Withdrawn due to a change in therapeutic interventions.” (69% match in meaning)
• Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
  “Withdrawn due to toxicity” (68% match in meaning)
• The Sub-Sero Study
  “Drug supply withdrawn (dec 2019)” (66% match in meaning)
• A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)
  “Withdrawn for administrative reasons” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.